Trung Huynh
Stock Analyst at RBC Capital
(4.48)
# 208
Out of 5,182 analysts
63
Total ratings
59.09%
Success rate
21.4%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Trung Huynh
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MRK Merck & Co. | Reiterates: Outperform | $142 | $119.07 | +19.26% | 6 | Mar 30, 2026 | |
| PFE Pfizer | Initiates: Underperform | $25 | $27.56 | -9.29% | 7 | Feb 25, 2026 | |
| LLY Eli Lilly and Company | Initiates: Outperform | $1,250 | $927.03 | +34.84% | 11 | Feb 25, 2026 | |
| BMY Bristol-Myers Squibb Company | Initiates: Sector Perform | $60 | $60.17 | -0.28% | 6 | Feb 25, 2026 | |
| ABBV AbbVie | Initiates: Outperform | $260 | $208.38 | +24.77% | 2 | Feb 25, 2026 | |
| REGN Regeneron Pharmaceuticals | Maintains: Neutral | $595 → $660 | $750.57 | -12.07% | 5 | Nov 7, 2025 | |
| INSM Insmed | Maintains: Buy | $194 → $223 | $144.48 | +54.35% | 9 | Oct 31, 2025 | |
| JSPR Jasper Therapeutics | Maintains: Buy | $29 → $25 | $1.02 | +2,350.98% | 3 | Aug 15, 2025 | |
| AMGN Amgen | Maintains: Neutral | $326 → $317 | $355.30 | -10.78% | 6 | Aug 6, 2025 | |
| CLDX Celldex Therapeutics | Maintains: Buy | $44 → $38 | $34.55 | +9.99% | 2 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $10 → $7 | $3.44 | +103.49% | 2 | Apr 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $13 | $9.93 | +30.92% | 1 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $170 → $175 | $234.18 | -25.27% | 2 | Jul 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $8.75 | - | 1 | Mar 23, 2021 |
Merck & Co.
Mar 30, 2026
Reiterates: Outperform
Price Target: $142
Current: $119.07
Upside: +19.26%
Pfizer
Feb 25, 2026
Initiates: Underperform
Price Target: $25
Current: $27.56
Upside: -9.29%
Eli Lilly and Company
Feb 25, 2026
Initiates: Outperform
Price Target: $1,250
Current: $927.03
Upside: +34.84%
Bristol-Myers Squibb Company
Feb 25, 2026
Initiates: Sector Perform
Price Target: $60
Current: $60.17
Upside: -0.28%
AbbVie
Feb 25, 2026
Initiates: Outperform
Price Target: $260
Current: $208.38
Upside: +24.77%
Regeneron Pharmaceuticals
Nov 7, 2025
Maintains: Neutral
Price Target: $595 → $660
Current: $750.57
Upside: -12.07%
Insmed
Oct 31, 2025
Maintains: Buy
Price Target: $194 → $223
Current: $144.48
Upside: +54.35%
Jasper Therapeutics
Aug 15, 2025
Maintains: Buy
Price Target: $29 → $25
Current: $1.02
Upside: +2,350.98%
Amgen
Aug 6, 2025
Maintains: Neutral
Price Target: $326 → $317
Current: $355.30
Upside: -10.78%
Celldex Therapeutics
May 9, 2025
Maintains: Buy
Price Target: $44 → $38
Current: $34.55
Upside: +9.99%
Apr 1, 2025
Maintains: Buy
Price Target: $10 → $7
Current: $3.44
Upside: +103.49%
Oct 10, 2024
Initiates: Buy
Price Target: $13
Current: $9.93
Upside: +30.92%
Jul 21, 2023
Maintains: Neutral
Price Target: $170 → $175
Current: $234.18
Upside: -25.27%
Mar 23, 2021
Upgrades: Outperform
Price Target: n/a
Current: $8.75
Upside: -